Literature DB >> 32464706

The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children.

Mark R Deneau1, Cara Mack2, Emily R Perito3, Amanda Ricciuto4, Pamela L Valentino5, Mansi Amin6, Achiya Z Amir7, Madeleine Aumar8, Marcus Auth9, Annemarie Broderick10, Matthew DiGuglielmo11, Laura G Draijer12, Eleonora Druve Tavares Fagundes13, Wael El-Matary14, Federica Ferrari15, Katryn N Furuya16, Nitika Gupta17, Jessica T Hochberg18, Matjaz Homan19, Simon Horslen20, Raffaele Iorio21, M Kyle Jensen1, Maureen M Jonas22, Binita M Kamath4, Nanda Kerkar23, Kyung Mo Kim24, Kaija-Leena Kolho25, Bart G P Koot12, Trevor J Laborda1, Christine K Lee22, Kathleen M Loomes26, Mercedes Martinez27, Alexander Miethke28, Tamir Miloh18, Douglas Mogul29, Saeed Mohammad30, Parvathi Mohan31, Stacy Moroz32, Nadia Ovchinsky33, Sirish Palle34, Alexandra Papadopoulou35, Girish Rao36, Alexandre Rodrigues Ferreira13, Pushpa Sathya37, Kathleen B Schwarz29,38, Uzma Shah39, Eyal Shteyer40, Ruchi Singh28, Vratislav Smolka41, Nisreen Soufi32, Atsushi Tanaka42, Raghu Varier43, Bernadette Vitola44, Marek Woynarowski45, Melissa Zerofsky46, Andréanne Zizzo47, Stephen L Guthery1.   

Abstract

BACKGROUND AND AIMS: Disease progression in children with primary sclerosing cholangitis (PSC) is variable. Prognostic and risk-stratification tools exist for adult-onset PSC, but not for children. We aimed to create a tool that accounts for the biochemical and phenotypic features and early disease stage of pediatric PSC. APPROACH AND
RESULTS: We used retrospective data from the Pediatric PSC Consortium. The training cohort contained 1,012 patients from 40 centers. We generated a multivariate risk index (Sclerosing Cholangitis Outcomes in Pediatrics [SCOPE] index) that contained total bilirubin, albumin, platelet count, gamma glutamyltransferase, and cholangiography to predict a primary outcome of liver transplantation or death (TD) and a broader secondary outcome that included portal hypertensive, biliary, and cancer complications termed hepatobiliary complications (HBCs). The model stratified patients as low, medium, or high risk based on progression to TD at rates of <1%, 3%, and 9% annually and to HBCs at rates of 2%, 6%, and 13% annually, respectively (P < 0.001). C-statistics to discriminate outcomes at 1 and 5 years were 0.95 and 0.82 for TD and 0.80 and 0.76 for HBCs, respectively. Baseline hepatic fibrosis stage was worse with increasing risk score, with extensive fibrosis in 8% of the lowest versus 100% with the highest risk index (P < 0.001). The model was validated in 240 children from 11 additional centers and performed well.
CONCLUSIONS: The SCOPE index is a pediatric-specific prognostic tool for PSC. It uses routinely obtained, objective data to predict a complicated clinical course. It correlates strongly with biopsy-proven liver fibrosis. SCOPE can be used with families for shared decision making on clinical care based on a patient's individual risk, and to account for variable disease progression when designing future clinical trials.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32464706      PMCID: PMC8557635          DOI: 10.1002/hep.31393

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  38 in total

1.  Small-duct primary sclerosing cholangitis: a long-term follow-up study.

Authors:  Paul Angulo; Yaakov Maor-Kendler; Keith D Lindor
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

Review 2.  The logrank test.

Authors:  J Martin Bland; Douglas G Altman
Journal:  BMJ       Date:  2004-05-01

3.  Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.

Authors:  Jens J W Tischendorf; Hartmut Hecker; Martin Krüger; Michael P Manns; Peter N Meier
Journal:  Am J Gastroenterol       Date:  2006-10-13       Impact factor: 10.864

4.  A method for checking regression models in survival analysis based on the risk score.

Authors:  J K Grønnesby; O Borgan
Journal:  Lifetime Data Anal       Date:  1996       Impact factor: 1.588

5.  Validation of a cholangiographic prognostic model in primary sclerosing cholangitis.

Authors:  C Y Ponsioen; J B Reitsma; K M Boberg; L Aabakken; E A Rauws; E Schrumpf
Journal:  Endoscopy       Date:  2010-07-09       Impact factor: 10.093

6.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

7.  Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course.

Authors:  Mark Deneau; Emily Perito; Amanda Ricciuto; Nitika Gupta; Binita M Kamath; Sirish Palle; Bernadette Vitola; Vratislav Smolka; Federica Ferrari; Achiya Z Amir; Tamir Miloh; Alexandra Papadopoulou; Parvathi Mohan; Cara Mack; Kaija-Leena Kolho; Raffaele Iorio; Wael El-Matary; Veena Venkat; Albert Chan; Lawrence Saubermann; Pamela L Valentino; Uzma Shah; Alexander Miethke; Henry Lin; M K Jensen
Journal:  J Pediatr       Date:  2019-03-14       Impact factor: 4.406

8.  The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.

Authors:  Mark R Deneau; Wael El-Matary; Pamela L Valentino; Reham Abdou; Khaled Alqoaer; Mansi Amin; Achiya Z Amir; Marcus Auth; Fateh Bazerbachi; Annemarie Broderick; Albert Chan; Jillian Cotter; Sylvia Doan; Mounif El-Youssef; Federica Ferrari; Katryn N Furuya; Madeleine Gottrand; Frederic Gottrand; Nitika Gupta; Matjaz Homan; Binita M Kamath; Kyung Mo Kim; Kaija-Leena Kolho; Anastasia Konidari; Bart Koot; Raffaele Iorio; Oren Ledder; Cara Mack; Mercedes Martinez; Tamir Miloh; Parvathi Mohan; Niamh O'Cathain; Alexandra Papadopoulou; Amanda Ricciuto; Lawrence Saubermann; Pushpa Sathya; Eyal Shteyer; Vratislav Smolka; Atushi Tanaka; Raghu Varier; Veena Venkat; Bernadette Vitola; Miriam B Vos; Marek Woynarowski; Jason Yap; M Kyle Jensen
Journal:  Hepatology       Date:  2017-06-26       Impact factor: 17.425

9.  Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets.

Authors:  Serap Turan; Burcu Topcu; İbrahim Gökçe; Tülay Güran; Zeynep Atay; Anjumanara Omar; Teoman Akçay; Abdullah Bereket
Journal:  J Clin Res Pediatr Endocrinol       Date:  2011-02-23

10.  Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study.

Authors:  D Kornfeld; A Ekbom; T Ihre
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

View more
  3 in total

1.  Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent.

Authors:  Cynthia W Buness; Kevin M Johnson; Ahmad Hassan Ali; Leina Alrabadi; Keith D Lindor; Tamir Miloh; Kenneth L Cox
Journal:  Clin J Gastroenterol       Date:  2020-11-24

2.  Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis.

Authors:  Mark R Deneau; Cara Mack; Douglas Mogul; Emily R Perito; Pamela L Valentino; Achiya Z Amir; Matthew DiGuglielmo; Laura G Draijer; Wael El-Matary; Katryn N Furuya; Nitika Gupta; Jessica T Hochberg; Simon Horslen; M Kyle Jensen; Maureen M Jonas; Nanda Kerkar; Bart G P Koot; Trevor J Laborda; Christine K Lee; Kathleen M Loomes; Mercedes Martinez; Alexander Miethke; Tamir Miloh; Saeed Mohammad; Nadia Ovchinsky; Girish Rao; Amanda Ricciuto; Pushpa Sathya; Kathleen B Schwarz; Uzma Shah; Ruchi Singh; Bernadette Vitola; Andréanne Zizzo; Stephen L Guthery
Journal:  Hepatology       Date:  2021-03       Impact factor: 17.425

3.  Use of oral vancomycin in children with autoimmune liver disease: A single centre experience.

Authors:  Angelo Di Giorgio; Anna Tulone; Emanuele Nicastro; Lorenzo Norsa; Aurelio Sonzogni; Lorenzo D'Antiga
Journal:  World J Hepatol       Date:  2021-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.